Overall survival in TP53-mutated AML and MDS
Puzo C, Hager K, Rinder H, Weinberg O, Siddon A. Overall survival in TP53-mutated AML and MDS. Annals Of Hematology 2024, 1-11. PMID: 39443370, DOI: 10.1007/s00277-024-06054-7.Peer-Reviewed Original ResearchOverall survivalBlast countTP53 mutationsSignificant predictors of OSP53 mutation typePredictors of OSAggressive disease biologyRetrospective chart reviewKaplan-Meier curvesYale-New Haven HospitalNext generation sequencingCox proportional hazards modelsProportional hazards modelComplex karyotypePoor OSP53 mutationsWHO criteriaChart reviewNew Haven HospitalPoor prognosisCo-mutationsPathogenic mutationsAMLICCS guidelinesMutation typeThe effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, lmae080. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixafor